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First discovered inDrosophila, the Hippo signaling pathway is a conserved regulator of organ size. Central to
this pathway is a kinase cascade leading from the tumor suppressor Hippo (Mst1 and Mst2 in mammals) to
the oncoprotein Yki (YAP and TAZ in mammals), a transcriptional coactivator of target genes involved in cell
proliferation and survival. Here, I review recent progress in elucidating the molecular mechanism and phys-
iological function of Hippo signaling in Drosophila and mammals. These studies suggest that the core Hippo
kinase cascade integrates multiple upstream inputs, enabling dynamic regulation of tissue homeostasis in
animal development and physiology.Introduction
The control of organ size is a long-standing puzzle in develop-
mental biology. Classic embryological studies suggest that
many organs possess intrinsic information about their final
size. For example, when two-thirds of a mouse liver is surgically
removed, the remaining one-third regenerates its original mass
within 7–10 days and then ceases growth (reviewed in Michalo-
poulos and DeFrances, 1997). Similarly, when imaginal discs
from newly hatched larvae are transplanted into adult flies,
they grow to a final size characteristic of that seen in situ (Bryant
and Simpson, 1984). Themolecular mechanisms that stop organ
growth at the appropriate point during development or regener-
ation remain poorly understood today.
The discovery of the Hippo signaling pathway provides an
important entry point to addressing these long-standing ques-
tions. The first four components of the Hippo pathway, including
the NDR family protein kinase Warts (Wts) (Justice et al., 1995;
Xu et al., 1995), the WW domain-containing protein Salvador
(Sav) (Tapon et al., 2002; Kango-Singh et al., 2002), the Ste20-
like protein kinase Hippo (Hpo) (Wu et al., 2003; Udan et al.,
2003; Harvey et al., 2003; Jia et al., 2003; Pantalacci et al.,
2003) and the adaptor protein Mob-as-tumor-suppressor
(Mats) (Lai et al., 2005), were discovered in genetic screens in
Drosophila for tumor suppressor genes. Loss-of-functionmutant
clones for any of these four genes lead to a strong tissue over-
growth phenotype characterized by increased proliferation and
diminished cell death. Biochemically, these four tumor suppres-
sors form a kinase cascade in which the Hpo-Sav kinase
complex phosphorylates and activates the Wts-Mats kinase
complex (Wu et al., 2003; Wei et al., 2007). The prime target of
this kinase cascade in growth regulation is transcriptional coac-
tivator Yorkie (Yki), which was isolated as a Hippo pathway
component in a yeast two-hybrid screen for Wts-binding
proteins (Huang et al., 2005). Yki functions as an oncogene
and its overexpression phenocopies loss of Hippo signaling.
Genetic analysis placed yki downstream of hpo, sav or wts,
and biochemical studies demonstrated that Wts directly
phosphorylates and inactivates Yki in a Hpo-regulated manner
(Huang et al., 2005). Thus, from these pioneering studies,a kinase cascade leading from Hpo to Yki phosphorylation
emerged (reviewed in Edgar, 2006; Pan, 2007).
The elucidation of the Hippo kinase cascade in Drosophila
has stimulated intense research into the molecular mechanism
and the physiological function of this emerging pathway in
both flies and vertebrates. While still a relatively young field,
research on Hippo signaling is escalating rapidly. Here, I review
current understanding of the Hippo signaling network in
Drosophila and mammals, its diverse roles in multiple physiolog-
ical contexts, and its involvement in cancer development, high-
lighting important progress in the past 3 years.
The Hippo Signaling Network in Drosophila
Following the discovery of the four tumor suppressors that
constitute the core kinase cassette, candidate gene-based
approaches and forward genetic screens have implicated at
least seven additional tumor suppressors whose activities
converge on Hpo and/or Wts. These include the FERM domain
proteins Merlin (Mer) and Expanded (Ex), the protocadherins
Fat (Ft) and Dachsous (Ds), the CK1 family kinase Disc over-
grown (Dco), the WW and C2 domain-containing protein Kibra,
and the apical transmembrane protein Crumbs (Crb) (Table 1).
While the mechanisms by which these upstream regulators
converge on the Hippo kinase cascade are complex and in
some instances unresolved, a notable feature is that mutations
in each of these genes lead to a relatively mild overgrowth
phenotype, suggesting that these upstream components func-
tion in a combinatorial or additive manner to regulate the Hippo
kinase cassette.
An Apical Protein Complex Containing Kibra, Ex,
and Merlin
The initial discovery of the Hippo kinase cascade posed a major
question: howdoes this intracellular signalingmodule respond to
extracellular cues? The first advance in addressing this question
was provided by Hamaratoglu et al. (2006), who implicated
Merlin (Mer) and Expanded (Ex)—two members of the ‘‘4.1,
Ezrin, Radixin, Moesin’’ (FERM) domain-containing family of
proteins—as potential upstream regulators of Hpo. Mer and Ex
bind to each other and colocalize to the apical domain ofDevelopmental Cell 19, October 19, 2010 ª2010 Elsevier Inc. 491
Table1. Hippo Pathway Components in Drosophila and Human
Drosophila Human
Conserved Domains
and Motifs
The Core Pathway
Hippo Mst1-2 Ste20 Ser/Thr kinase
and SARAH domains
Salvador Sav1/WW45 WW and SARAH domain
Warts Lats1-2 NDR Ser/Thr kinase
domain, PPXY motif
Mats MOBKL1A-B Mob1/phocein domain
Yorkie YAP, TAZ WW and TEAD-binding
domains
Scalloped TEAD1-4 TEA/ATTS and Yki/YAP-
binding domains
Upstream Apical Complex
Kibra KIBRA/WWC1,WWC2 WW and C2 domains
Expanded FRMD6/Ex1,FRMD1/Ex2 FERM domain
Merlin NF2/Merlin FERM domain
Fat Effectors and Regulators
Fat Fat4/Fat-j EGF-like, Laminin G and
Cadherin repeat domains
Dachsous Dchs1-2 Cadherin repeat domain
Four-jointed Fjx1 Golgi Ser/Thr kinase
Dachs ? Myosin motor domain
Discs overgrown CK1d, CK13 Ser/Thr kinase domain
Approximated ZDHHC14 DHHC zinc finger domain
Lowfat Lix1, Lix1L unknown conserved
domain
Apical-Basal Polarity
Crumbs Crb1-3 EGF-like and Laminin
G domains, PDZ- and
FERM-binding motifs
Lgl Lgl1-2 LLGL2 domain
aPKC aPKCl, aPKCz PKC kinase, PB1
and C1 domains
Other Modulators
dRASSF RASSF1-6 Ras association and
SARAH domains
dSTRIPAK
PP2A
STRIPAK PP2A PP2A Ser/Thr
phosphatase complex
dJuba Ajuba, LIMD1, WTIP LIM domain
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function in a partially redundant manner to regulate the Hippo
pathway, as doublemutant clones display amuch stronger over-
growth phenotype than mutants of either gene (Hamaratoglu
et al., 2006). Consistent with the genetic analysis, overexpres-
sion of Mer and Ex was shown to promote Wts phosphorylation
in a cooperativemanner. Given the general role of FERMproteins
as adaptors that bridge transmembrane proteins to the cytoskel-
eton, Mer and Ex are uniquely positioned to link the Hippo kinase
cascade to potential transmembrane receptors.
Three recent reports identified the WW and C2 domain-con-
taining protein Kibra as another apically localized tumor
suppressor that functions together with Mer and Ex to stimulate492 Developmental Cell 19, October 19, 2010 ª2010 Elsevier Inc.Hippo signaling (Yu et al., 2010; Baumgartner et al., 2010;
Genevet et al., 2010). Kibra, Ex and Mer cooperatively promote
Wts phosphorylation, and accordingly, double mutant combina-
tions among the three genes revealed stronger Hippo signaling
defects than any single mutants. The Kibra-Ex-Mer protein
complex physically associates with the Hpo-Sav complex and
is required for membrane association of Hpo (Yu et al., 2010).
Interaction between Kibra and Wts was also reported (Genevet
et al., 2010). Thus, the Kibra-Ex-Mer complex appears to interact
with the Hippo kinase cascade through multiple protein-protein
interactions, and these physical interactions are likely critical
for bringing the Hippo kinase cassette to plasma membrane
for activation. Indeed, a recent study provided direct evidence
demonstrating that the tumor suppressor Mats is activated at
the cell membrane (Ho et al., 2010). Interestingly, the expression
of these upstream apical regulators is negatively regulated by
Hippo signaling, as hpo, sav, or wts mutant clones have been
reported to show increased transcript levels of kibra and ex, as
well as elevated protein levels of Kibra, Ex, and Mer (Genevet
et al., 2010; Hamaratoglu et al., 2006).
Unlike protein complexes, such as TSC1-TSC2, in which each
component is obligatory to the function of the whole complex,
components of the Kibra-Ex-Mer complex appear to function
in a partially redundant manner to regulate Hippo signaling.
Furthermore, the extent to which each component contributes
to Hippo pathway regulation varies according to the tissue
type. For example, diap1 regulation is primarily dependent on
ex in imaginal discs (Pellock et al., 2006), while mer and kibra
are more strongly required in the developing egg chamber for
the proper maturation of posterior follicle cells and anterior-
posterior polarity of the underlying oocyte (Yu et al., 2008,
2010; Polesello and Tapon, 2007; Meignin et al., 2007). Along
the same line, it was suggested that Ex is preferentially required
for Hippo signaling in the larval eye whereas Mer is preferentially
required in the pupal eye (Milton et al., 2010). Thus, the Kibra-Ex-
Mer complex may function as a dynamic integrator of upstream
signals in a temporally and spatially regulated manner.
Transmembrane Protein Fat: Regulation and Function
The atypical cadherin Fat (Ft) was the first transmembrane
protein shown to impact Hippo signaling (Bennett and Harvey,
2006; Silva et al., 2006; Willecke et al., 2006; Cho et al., 2006;
Tyler and Baker, 2007). Ft is constitutively cleaved by an
unknown protease(s); the N-terminal 450 kDa extracellular
domain forms a stable heterodimer with the C-terminal 110 kDa
transmembrane fragment (Sopko et al., 2009; Feng and
Irvine, 2009). Besides its role as a growth regulator, Ft also
affects planar cell polarity (PCP) (Yang et al., 2002; Casal et al.,
2006), a process by which cells in the plane of an epithelium
orient themselves along an axis orthogonal to the apical-basal
axis, as seen in the coordinated orientation of wing hairs in
Drosophila or sensory hair cells in the mouse inner ear. So far,
two distinct mechanisms have been proposed to link Ft to Hippo
signaling. In one model, it was proposed that Ft, Ex, and Hpo
function in a linear pathway whereby Ft is required for apical
membrane localization and/or stability of Ex (Bennett and
Harvey, 2006; Silva et al., 2006; Willecke et al., 2006). In an alter-
native model, it was proposed that Ft and Ex function in parallel
with each other, with Ft and Ex influencing the protein level and
the phosphorylation of Wts protein, respectively (Cho et al.,
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resolve thesemodels, and the possibility exists that Ft may regu-
late Hippo signaling through both Ex-dependent and -indepen-
dent mechanisms.
The key downstream mediator of Ft action on the Hippo
pathway is the unconventional myosin Dachs, which functions
antagonistically to Ft and upstream of Wts (Cho et al., 2006).
Dachs associates with Wts when overexpressed in Drosophila
cell cultures and may function by promoting Wts proteolysis.
Interestingly, Ft activity regulates preferential accumulation of
the Dachs protein on the distal side of the wing imaginal disc
epithelial cells (Rogulja et al., 2008). Another protein that impacts
Dachs activity is the palmitoyltransferase Approximated (App),
which antagonizes Ft signaling by regulating the levels and
subcellular localization of Dachs (Matakatsu and Blair, 2008).
Whether this function is mediated by palmitoylation of Dachs
or an unknown regulator of Dachs remains to be determined.
Ft functions by binding to another atypical cadherin called
Dachsous (Ds) (Matakatsu and Blair, 2006), a process that is
modulated by Four-jointed (Fj), a Golgi-resident kinase that
phosphorylates the cadherin domains of Ft andDs as they transit
through the Golgi network (Ishikawa et al., 2008). Interestingly,
Fj and Ds are expressed in opposing gradients in many devel-
oping tissues, and their expression, in turn, is regulated by
morphogens such as Decapentaplegic (Dpp, a BMP), Wingless
(a Wnt), and Hedgehog (Yang et al., 2002; Casal et al., 2006;
Rogulja et al., 2008), providing a potential mechanism to coordi-
nate tissue size (growth) with tissue shape (patterning). Fj-medi-
ated phosphorylation enhances the ability of Ft to bind Ds while
inhibiting the ability of Ds to bind Ft, which suggests a molecular
mechanism for how the graded expression of Fj across many
Drosophila tissues can be translated to polarized Ft activity
within every cell as reflected by the polarized localization of
Dachs (Simon et al., 2010; Brittle et al., 2010). Another modulator
of Ft is the casein kinase Discs overgrown (Dco), which can
phosphorylate the intracellular domain of Ft in a Ds-regulated
manner (Sopko et al., 2009; Feng and Irvine, 2009). A recently
identified regulator of Ft is Lowfat (Lft), a conserved cytoplasmic
protein that binds to the cytoplasmic domains of Ft and Ds
and influences the stability of the latter (Mao et al., 2009).
Conversely, Ft and Ds control the sub-apical localization of Lft
(Mao et al., 2009).
The Ds-Ft system has several unusual characteristics that
distinguish it from conventional receptor-ligand interactions.
First, Ft signaling is regulated not simply by the amount of Ds,
but rather by the steepness of the Ds gradient (Rogulja et al.,
2008; Willecke et al., 2008). A steep gradient of Ds inactivates
Ft, whereas a shallow gradient activates Ft. Second, Ds is
required in both signal-sending cells as well as signal-respond-
ing cells, suggesting that Ds has both ligand- and receptor-like
activity (Willecke et al., 2008; Casal et al., 2006). Lastly, Ds and
Fj have opposite effects on Ft-dependent PCP signaling (and
are indeed expressed in opposing gradients in many tissues)
(Casal et al., 2002; Strutt and Strutt, 2002; Yang et al., 2002)
but have similar effects on Ft-dependent Hippo signaling
(Rogulja et al., 2008; Willecke et al., 2008). These contrasting
effects can be explained by a model in which PCP is regulated
by the directionality of Ft polarization within a cell, whereas
Hippo signaling is regulated by the magnitude of the differentialpolarization when one compares opposite sides of the cell
(Rogulja et al., 2008; Willecke et al., 2008).
Transmembrane Protein Crumbs: A Link
to Apical-Basal Polarity
Despite a clear influence of Ft on Hippo signaling in imaginal
discs, several lines of evidence argue against a simple model
that positions Ft as the sole cell-surface receptor for the Hippo
pathway. Loss of Ft generally results in a weaker phenotype
than mutations of the Hippo kinase cassette. For example, hpo
or wts mutant clones in the pupal retina are characterized by a
signature ‘‘extra interommatidial cell’’ phenotype with >40 extra
cells per ommatidium. In contrast, ft mutant clones contain an
average of 3.3 extra cells per ommatidium (Silva et al., 2006).
An even greater dichotomy is seen in the developing egg
chamber in which ft, but not the core kinase cassette or the
Kibra-Ex-Mer complex, is dispensable for posterior follicle cell
differentiation and oocyte polarity (Polesello and Tapon, 2007;
Meignin et al., 2007; Yu et al., 2008). Thus, depending on the
tissue context, the Kibra-Ex-Mer complex is regulated by signals
in addition to or instead of Ft. Consistent with this view, ft mer
double mutant clones show a much stronger ‘‘extra interomma-
tidial cell’’ phenotype in pupal retina compared to single mutant
clones, suggesting that Mer may transduce a signal from an
unknown cell surface receptor (Silva et al., 2006; Willecke
et al., 2006). Thus, there has been intense interest in identifying
additional cell surface proteins that signal to the Hippo pathway.
Crumbs (Crb) is an apical transmembrane protein best known
for its role in organizing apical-basal polarity in Drosophila
embryos (Tepass et al., 1990). It contains 28 EGF-like and four
laminin AG-like repeats in its extracellular domain and a short
intracellular domain including a juxtamembrane FERM-binding
motif (FBM) and a C-terminal PDZ-binding motif (PBM). Crb
forms a protein complex with the apical polarity proteins
Stardust (Sdt) and Patj through its PBM (Bachmann et al.,
2001; Hong et al., 2001; Bhat et al., 1999), but the molecular
function of Crb’s FBMhas been less clear. Several recent studies
reported that the FBM affects Ex stability and localization
(Robinson et al., 2010; Ling et al., 2010; Chen et al., 2010a).
Indeed, the FBM of Crb binds to the FERM domain of Ex and
is required for Ex apical localization, and double mutant analysis
revealed that Crb functions with Ex in a linear pathway, but in
parallel with Mer and Kibra (Ling et al., 2010). Conversely, Crb
overexpression induces FBM-dependent tissue overgrowth
and depletion of apical Ex protein likely from a dominant-nega-
tive effect (Robinson et al., 2010; Chen et al., 2010a). Like other
upstream regulators of the Hippo pathway such as kibra and ex,
transcription of crb is negatively regulated by Hippo signaling,
although to a lesser extent (Genevet et al., 2009).
Are there other links between apical-basal polarity and Hippo
signaling? Loss of Lgl (a basolateral protein) or activation of
aPKC (a component of a different apical protein complex) can
both mislocalize Hpo and upregulate selected Hippo pathway
target genes (Grzeschik et al., 2010). Further studies are required
to fully elucidate which manifestations of polarity impact the
Hippo signaling pathway and how this coupling works at a
biochemical level.
All Roads Lead to Rome: Regulation of Yki Activity
While the regulation of Hippo signaling by upstream components
seems dauntingly complex, these upstream components allDevelopmental Cell 19, October 19, 2010 ª2010 Elsevier Inc. 493
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regulatory effector, the transcriptional coactivator Yki. Indeed,
Wts directly phosphorylates Ser168 of Yki, creating a binding
site for 14-3-3 proteins, which promote nuclear exclusion and
cytoplasmic accumulation of Yki (Dong et al., 2007; Zhao
et al., 2007; Oh and Irvine, 2008). Consistent with this model,
loss of Hippo signaling (Dong et al., 2007; Oh and Irvine, 2008),
knockdown of 14-3-3 (Ren et al., 2010), or mutation of the
14-3-3 binding motif (Zhao et al., 2007) all lead to nuclear accu-
mulation and/or aberrant activation of endogenous Yki. Wts can
also influence the activity and nuclear localization of overex-
pressed Yki via two additional sites (at S111 and S250), albeit
to a lesser extent than S168, and independently of 14-3-3 (Oh
and Irvine, 2009; Ren et al., 2010). It remains to be determined
what contribution and mechanism of action S111 and S250
phosphorylation might have in the context of endogenous Yki
activity.
Two recent studies have also shown that direct binding
between the WW domains of Yki and the PPxY motifs of Ex,
Wts and Hpo may sequester Yki (Badouel et al., 2009; Oh
et al., 2009). This repression was suggested to be phosphoryla-
tion-independent, based on the observation that overexpressed
Ex and/or Wts/Hpo can repress the activity of a Yki transgene
that eliminates all three possible Wts phosphorylation sites
(Oh et al., 2009). Further study is needed to assess the contribu-
tion of this mode of regulation under physiological conditions,
e.g., at endogenous levels of Ex/Wts/Hpo and Yki. Because
the PPxY motifs implicated in Ex-Yki and Hpo-Yki binding are
absent in the mammalian homologs of Hpo and Ex, these
mammalian homologs are unlikely to engage a similar phosphor-
ylation-independent mechanism.
Transcriptional Regulation by Yki: Partners and Targets
As a transcriptional coactivator, Yki does not bind to DNA
directly but, rather, partners with DNA-binding transcription
factors, such as the TEAD/TEF family transcription factor Scal-
loped (Sd), which mediates Yki-induced tissue overgrowth
(Wu et al., 2008; Zhang et al., 2008; Goulev et al., 2008). Sd
directly binds to a minimal 26 bp Hippo response element
(HRE) that confers Hippo-dependent transcriptional regulation
of diap1, a well characterized Hippo target gene (Wu et al.,
2008). That said, Sd, but not Yki, is largely dispensable for the
normal growth of imaginal discs, suggesting that other DNA-
binding transcription factors regulate target gene expression in
response to basal levels of Yki activity. Indeed, the minimal
diap1 HRE contains non-Sd-binding sequence that is indispens-
able for activity (Wu et al., 2008). A relevant transcription factor
has not yet been identified, but other DNA-binding partners for
Yki have been reported recently. In one study, Homothorax
(Hth) was reported as a Yki partner that promotes cell survival
and proliferation anterior to the morphogenetic furrow in the
eye imaginal disc (Peng et al., 2009). In this cellular context,
Hth has minimal influence on the expression of diap1 but,
instead, regulates the expression of another Yki target, the
microRNA bantam. In another study, Smad proteins were
reported to interact with Yki/YAP (Alarco´n et al., 2009). CDK8/9,
components of transcriptional mediator and elongation com-
plexes, phosphorylate the Smad linker region, enabling its
binding to the WW domains of Yki. This interaction is believed
to potentiate the transcriptional response to BMP/TGF-b494 Developmental Cell 19, October 19, 2010 ª2010 Elsevier Inc.signaling, highlighting a possible crosstalk between Hippo and
BMP/TGF-b pathways. Because the WW domains are required
for endogenous Yki activity (Wu et al., 2008), it will be important
to determine whether the basal levels of Yki activity are medi-
ated by Smad or other unknown WW domain-binding transcrip-
tion factors.
Loss of Hippo signaling (or increased Yki activity) can drive the
expression of at least three classes of genes. The first class
corresponds to genes with a cell-autonomous role in cell prolif-
eration or survival, such as the cell death inhibitor diap1 (Wu
et al., 2003), the microRNA bantam (Thompson and Cohen,
2006; Nolo et al., 2006), and the cell-cycle regulators cyclin E
(Tapon et al., 2002) and E2F1 (Goulev et al., 2008). However,
Yki targets with direct roles in cell growth have remained elusive.
In this issue of Developmental Cell, Johnston and colleagues
have considerably filled this gap by identifying dMyc, a potent
regulator of ribosome biogenesis and cell growth, as a transcrip-
tional target of Yki. Interestingly, not only does Yki positively
regulate the expression of dMyc, dMyc also negatively regulates
Yki expression and activity. The negative feedback loop
between dMyc and Yki may suggest a homeostatic mechanism
that integrates the activity of two key mediators of size control
and offers a potential molecular explanation for Myc’s well-
documented proapoptotic activity (reviewed in Green and
Evan, 2002).
The second class of genes encode upstream regulators of the
Hippo pathway, such as Kibra, Ex, Crb, and Fj (Genevet et al.,
2010; Hamaratoglu et al., 2006; Genevet et al., 2009; Cho
et al., 2006). Feedback regulation of upstream pathway compo-
nents appears to be a common feature of many signaling
pathways, which has been suggested to play important roles in
maintaining steady-state levels of signaling strength (reviewed
in Stelling et al., 2004).
The third class of genes represent potential means of crosstalk
to other modes of cell-cell interaction and cell signaling, such as
E-Cadherin (Genevet et al., 2009), Serrate (a Notch ligand) and
Wingless (Cho et al., 2006), Vein (an EGFR ligand) (Zhang
et al., 2009b), and the heparan sulfate proteoglycans Dally and
Dally-like (Baena-Lopez et al., 2008), both of which are cell
surface proteins implicated in regulating the extracellular diffu-
sion and signal efficiency of secreted morphogens, including
Hedgehog, Dpp, andWingless. This complex crosstalk between
pathways regulating tissue growth and patterning may ensure
their coordination during animal development. Of note, with the
exception of diap1, Hippo responsive elements (HREs) have
not been molecularly defined for the known Hippo target genes.
A comprehensive understanding of the transcriptional landscape
in response to Hippo signaling will require functional dissection
of HREs in multiple Hippo target genes.
Future Directions for the Hippo Signaling Network
in Drosophila
It is conspicuous that the kinase cascade leading fromHpo to Yki
phosphorylation appears to be invariant and strictly required,
while the upstream inputs that influence kinase activity are
much more diverse and, indeed, partially redundant (Figure 1).
A major question in the field is to identify what features of cell
adhesion and polarity are the primary ‘‘signals’’ activating the
Hippo pathway and to understand how these signals are inter-
preted biochemically by the Hippo kinase cascade.
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Figure 1. The Hippo Signaling Network in Drosophila and Mammals
(A) Signaling diagram. Corresponding proteins in Drosophila and mammals are indicated by matching colors and shapes. Direct biochemical interactions
are indicated by solid lines or drawn as proteins in direct contact with each other. Dashed lines indicate genetic interactions for which no direct protein-protein
interactions have been reported. Arrowed or blunted ends indicate activation or inhibition, respectively. Also shown are selected target genes. Yki- or YAP/
TAZ-interacting transcription factors other than Sd (Drosophila) or TEAD (mammals) are collectively listed in a box.
(B) A normal (left) and a yki-overexpressing (right) Drosophila wing imaginal disc. Image adapted from Huang et al. (2005).
(C) A normal (left) and a YAP-overexpressing (right) mouse liver. Image adapted from Dong et al. (2007).
The dramatic increase in organ size induced by Yki/YAP overexpression illustrates the potent growth-regulatory activity of Hippo signaling in Drosophila and
mammals.
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downstream kinase cassette, the apical Kibra-Ex-Mer complex
is uniquely positioned as a platform for signal integration.
Besides Ft and Crb, which have been linked to this complex
via their effect on Ex localization and/or stability, it is conceivable
that additional cell-surface proteins may regulate this complex
through their influence on Kibra and Mer. While accumulating
evidence suggests that the Hippo kinase cascade is activated
at the plasma membrane, the biochemical mechanism of kinase
activation at the plasma membrane remains to be elucidated.
Also unknown is whether the Hippo kinase cassette can be
activated in additional subcellular compartments such as the
nucleus, where some components of the mammalian Hippo
kinase cassette have been implicated in controlling mitotic exitand centrosome duplication (Nishiyama et al., 1999; Bothos
et al., 2005; Guo et al., 2007; Hergovich et al., 2009).
Besides positive upstream regulators of Hippo signaling, addi-
tional nodes of signal integration may be provided by proteins
that negatively modulate the Hippo kinase cascade. Such
proteins include the aforementioned myosin-like protein Dachs
(Mao et al., 2006), the Drosophila Ras association family protein
dRASSF (Polesello et al., 2006), and the LIM family protein Ajuba
(Das Thakur et al., 2010). Like its mammalian counterparts,
dRASSF directly binds to Hpo, an interaction that is mediated
by the C-terminal SARAH domain of each protein (Polesello
et al., 2006). However, unlike its tumor suppressor counterparts
in mammals (see below), dRASSF functions as a positive
regulator of growth by competing with Sav for binding to HpoDevelopmental Cell 19, October 19, 2010 ª2010 Elsevier Inc. 495
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complex called dSTRIPAK (Ribeiro et al., 2010). The Ajuba
proteins inhibit Hippo signaling through physical interactions
with Wts and Sav (Das Thakur et al., 2010). While the precise
mechanism by which the Ajuba proteins influence the Hippo
kinase cascade remains to be determined, it is notable that the
Ajuba proteins are components of the adherens junctions (Marie
et al., 2003) and, thus, are ideally positioned to link the apical
upstream regulators to the downstream Hippo kinase cassette.
Overall, the Hippo kinase cascade appears to be regulated by
myriad upstream inputs, many of which are yet to be identified.
The Hippo Signaling Network in Mammals:
Conservation, Complexity, and Divergence
The discovery of the founding members of the Hippo signaling
pathway in Drosophila has provided a paradigm for investigating
Hippo signaling inmammals. While recent molecular and genetic
studies have experimentally validated some conserved aspects
of Hippo signaling in mammals, such as the composition of the
core kinase cascade and its role in organ size control, these
studies also revealed additional complexity and, in some cases,
divergence from Drosophila (Figure 1).
The Hippo Kinase Cascade in Mammals and Divergent
Mechanisms of YAP/TAZ Inactivation
Given its central position in Hippo signaling, earlier studies in
mammals have focused on the core kinase cascade. The
mammalian genome contains two Hpo homologs (Mst1 and
Mst2), one Sav homolog (WW45 or Sav1), two Wts homologs
(Lats1 and Lats2), and two Mats homologs (MOBKL1A and
MOBKL1B, often collectively referred to as Mob1). These
proteins form a conserved kinase cassette (Callus et al., 2006;
Praskova et al., 2008; Chan et al., 2005) that phosphorylates
and inactivates the mammalian Yki homologs YAP (Dong et al.,
2007; Zhao et al., 2007; Lei et al., 2008) and TAZ (Lei et al.,
2008) on multiple HxRxxS motifs in response to cell density, of
which only one (YAP S127 and TAZ S89, like Yki S168) serves
as a 14-3-3-binding site and plays the most critical role in
regulating nuclear-cytoplasmic translocation. This cell density-
dependent activation of Hippo signaling is required for contact
inhibition of cultured mammalian cells (Zhao et al., 2007). Thus,
a highly analogous Hippo kinase cascade appears to exist in
mammalian cells.
The physiological relevance of the conserved Hippo kinase
cascade was supported by studies of transgenic and knockout
mice. Transgenic overexpression of YAP (Dong et al., 2007;
Camargo et al., 2007) or liver-specific knockout of Mst1/2 or
Sav1 (Zhou et al., 2009; Lu et al., 2010; Song et al., 2010; Lee
et al., 2010) each expanded the liver size and ultimately induced
hepatocellular carcinoma (HCC), revealing a conserved role
for the Hippo pathway in regulating organ size in mammals.
Examination of Lats1/2 and YAP phosphorylation in Mst1/2- or
Sav1-deficient livers, however, has produced inconsistent
results concerning the specific requirement for Mst1/2 in
Lats1/2 phosphorylation (Zhou et al., 2009; Lu et al., 2010), as
well as the requirement for Sav1 in YAP phosphorylation (Lu
et al., 2010; Lee et al., 2010). There also appear to be tissue-
specific requirements for pathway components, as in contrast
to the murine liver, Mst1/2 are not required for YAP phosphory-
lation in immortalized mouse embryonic fibroblasts (Zhou496 Developmental Cell 19, October 19, 2010 ª2010 Elsevier Inc.et al., 2009). Such complexity may suggest the existence of non-
canonical components that replace certain canonical compo-
nents of the Hippo kinase cascade. Along this line, it was sug-
gested that an Mst1/2-regulated kinase distinct from Lats1/2
may be responsible for YAP phosphorylation in the murine liver
(Zhou et al., 2009). These recent findings highlight the complexity
and possible tissue-specific organization of the Hippo kinase
cascade in mammals.
Another unanticipated aspect of the mammalian Hippo kinase
cascade concerns the mechanism of YAP/TAZ inactivation.
While previous studies have focused on YAP nuclear-cyto-
plasmic translocation as amajor mechanism of YAP inactivation,
a recent report described an additional mode of regulation in
which phosphorylation of a specific HxRxxS motif at S381 by
Lats1/2 primes YAP for subsequent phosphorylation by CK1
delta/epsilon, followed by the recruitment of the E3 ubiquitin
ligase SCFb-TRCP and ubiquitin-mediated degradation of YAP
(Zhao et al., 2010). Both S381-mediated YAP degradation and
the previously described S127-mediated nuclear-cytoplasmic
translocation are critical for YAP inactivation because both phos-
phorylation sites must be mutated before YAP can transform
NIH 3T3 cells (Zhao et al., 2010). Interestingly, the S381 phos-
phodegron of YAP is conserved in TAZ, but not Yki, revealing
an important divergence between Drosophila and mammals.
Because the analysis of Lats1/2 phosphorylation sites in YAP/
TAZ has been carried out using overexpressed constructs, it
will be important to define the contribution of individual phos-
phorylation site or their combinations to the regulation of endog-
enous YAP/TAZ activity.
Transcriptional Regulation by YAP/TAZ: Partners
and Targets
Studies in mammalian cells have revealed multiple DNA-binding
transcription factor partners for YAP, such as the p53 family
member p73 (Strano et al., 2001), the Runt family member
Runx2 (Yagi et al., 1999), and the TEAD/TEF family transcription
factors (Vassilev et al., 2001). Likewise, TAZ has been reported to
interact with multiple DNA-binding transcription factors, such as
peroxisome proliferator-activated receptor g (Hong et al., 2005),
thyroid transcription factor-1 (Park et al., 2004), Pax3 (Murakami
et al., 2006), Tbx5 (Murakami et al., 2005), Runx2 (Cui et al.,
2003; Hong et al., 2005), TEAD1 (Mahoney et al., 2005), and
Smad2/3/4 (Varelas et al., 2008). Among these YAP/TAZ-inter-
acting proteins, the TEAD/TEF family transcription factors, which
represent homologs of the Drosophila Sd protein, have emerged
as the prime mediators of YAP/TAZ function in Hippo signaling
(Zhao et al., 2008; Ota and Sasaki, 2008; Zhang et al., 2009a;
Chan et al., 2009). The mammalian genome contains four highly
homologous TEAD/TEF familymembers (TEAD1 to -4), which are
expressed in diverse tissues from preimplantation embryos to
adult tissues (Kaneko and DePamphilis, 1998). Most adult
tissues express at least one TEAD member, and different
TEAD members appear to function in a redundant manner
(Sawada et al., 2008). Consistent with the view that the TEAD
transcription factors are the major mediators of YAP/TAZ func-
tion, TEAD1/TEAD2 and YAP were shown to regulate largely
overlapping sets of target genes (Zhao et al., 2008; Ota and
Sasaki, 2008), and RNAi of TEAD factors, or mutations in YAP/
TAZ that disrupt their interactions with TEAD factors, diminished
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growth and epithelial-mesenchymal transition (EMT) (Zhao
et al., 2008; Zhang et al., 2009a; Chan et al., 2009).
The list of transcriptional partners discussed above, and the
shared transactivation of TEAD factors in particular, suggests
that YAP and TAZ have partially separable functions but may
also be redundant in some crucial ways. Consistent with this
view, YAP null mice die at embryonic day 8.5 (Morin-Kensicki
et al., 2006) and TAZ null mice are viable (Hossain et al., 2007;
Tian et al., 2007; Makita et al., 2008), but mice lacking both
YAP and TAZ die extremely early, before the formation of
16-cell morula embryos (Nishioka et al., 2009). Parallel analysis
of gene expression profiles revealed common as well as distinct
target genes regulated by YAP and TAZ in human MCF10A
mammary epithelial cells (Zhang et al., 2009a). This raises the
question of whether target gene specificity is merely dependent
on the utilization of distinct DNA-binding partners or might
actually be guided by YAP and TAZ themselves. A precedent
for coactivator-dictated target specificity has been reported in
Drosophila, where Sd-Yki and Sd-Vg complexes can regulate
distinct target genes (Wu et al., 2008).
Comprehensive expression profiling has revealed a large
number of genes that are induced by YAP in mouse livers and
different cell lines in a context-dependent manner (Dong et al.,
2007; Zhao et al., 2007; Hao et al., 2008; Ota and Sasaki,
2008; Lu et al., 2010). Some of these genes, such as the IAP
family member BIRC5 (Dong et al., 2007), the secreted Cys-
tein-rich protein connective tissue growth factor (CTGF) (Zhao
et al., 2007; Zhang et al., 2009a), and the EGF family member
amphiregulin (AREG) (Zhang et al., 2009b), have been subjected
to secondary studies and shown to contribute to YAP-activated
growth in cell culture. Indeed, CTGF is a direct target of both YAP
and TAZ (Zhao et al., 2007; Zhang et al., 2009a), and AREG is
a direct target of YAP (Zhang et al., 2009b). In the future, it will
be important to examine whether these reported YAP/TAZ
targets contribute to Hippo signaling under physiological condi-
tions such as within intact mammalian tissues.
Upstream of the Mammalian Hippo Kinase Cascade
With the exception of Dachs, the mammalian genome contains
homologs for all the reported upstream regulators of the Hippo
pathway, including two Kibra homologs (KIBRA/WWC1 and
WWC2), two possible Ex homologs (FRMD6/Ex1 and FRMD1/
Ex2), one Mer homolog (NF2/Mer), one Ft homolog (Fat4/Fat-j),
two Ds homologs (Dchs1 and Dchs2), one Fj homolog (Fjx1),
two Lft homologs (Lix1 and Lix1-like), and three Crb homologs
(Crb1, Crb2 and Crb3) (Table 1). Loss-of-function mutations
are not available for most of these mammalian homologs, thus
preventing a rigorous dissection of their physiological functions.
However, genetic characterization of the few genes for which
loss-of-function mutations are available has revealed important
insights into upstream regulation of the mammalian Hippo
pathway.
Among the mammalian genes whose Drosophila counterparts
have been implicated as upstream regulators of Hippo signaling,
NF2/Mer has been most intensively studied (reviewed in
McClatchey and Giovannini, 2005; Okada et al., 2007). Mer/
NF2 was discovered nearly two decades ago as a tumor
suppressor whose mutations cause Neurofibromatosis 2, an
autosomal dominant disorder characterized by the developmentof benign schwannomas and other Schwann-cell-derived
tumors associated with the nervous system (Rouleau et al.,
1993; Trofatter et al., 1993). Since then, NF2/Mer has been linked
to a wide spectrum of effector pathways and cellular functions in
mammalian cells, such as Ras, Rac, STAT, or PI3K signaling, as
well as endocytosis/degradation of membrane receptors, such
as EGFR (reviewed in McClatchey and Giovannini, 2005; Okada
et al., 2007), or inhibition of the E3 ubiquitin ligase CRL4DCAF1 in
the nucleus (Li et al., 2010a). A particularly important aspect of
NF2 function from the standpoint of this review is its prominent
role in contact inhibition mediated by cell-surface receptors
(e.g., the hyaluronic acid receptor CD44; Morrison et al., 2001)
or adherens junctions. However, the relative contribution of
effector pathways to NF2 function has not been defined geneti-
cally in intact tissues. Recently, it was shown that inactivation of
Nf2 led to hepatocellular carcinoma (HCC) and bile duct tumors
(Zhang et al., 2010; Benhamouche et al., 2010). Intriguingly,
mutations in core Hippo pathway components, such as Mst1/2
(Yu et al., 2010; Lu et al., 2010) and Sav1 (Lee et al., 2010), reveal
similar dual tumor phenotypes, and it has been proposed that
this dual effect on hepatocyte and cholangiocyte proliferation
may reflect the expansion of oval cells, putative bipotential liver
progenitor cells (Benhamouche et al., 2010; Lee et al., 2010; Yu
et al., 2010; Lu et al., 2010). That said, cholangiocyte tumors
were not observed in studies of YAP-transgenic livers (Dong
et al., 2007; Camargo et al., 2007), and further work is needed
to evaluate the apparent discrepancy as well as the (patho)phys-
iological nature of oval cell lineages in vivo.
Strikingly, loss of Yap leads to loss of hepatocytes and biliary
epithelial cells, whereas heterozygous deletion of Yap, which
results in no phenotypical manifestation by itself, significantly
suppressed the Nf2-deficient liver phenotypes as well as cata-
ract formation caused by Nf2-deficiency in the lens epithelium
(Zhang et al., 2010). These findings provide strong genetic
evidence placing NF2/Mer upstream of the mammalian Hippo
signaling pathway in a physiological setting. This relationship
may not be entirely straightforward, however, as NF2/Mer also
controls liver homeostasis through EGFR signaling (Benha-
mouche et al., 2010), and conflicting evidence for Hippo pathway
regulation by NF2 was reported (Zhang et al., 2010; Benha-
mouche et al., 2010). It is worth noting in this context that
overexpressed human homologs of some components of the
Drosophila Kibra-Ex-Mer complex can physically interact with
each other (Genevet et al., 2010; Yu et al., 2010) or with canonical
Hippo pathway components (Yu et al., 2010) and can stimulate
Lats1/2 phosphorylation (Yu et al., 2010) or inhibit YAP activity
(Zhao et al., 2007) in mammalian cell cultures. Of note, the Ex
homolog FRMD6 does not contain the extended C-terminal
region, which Ex requires for its growth-inhibitory activity
(Boedigheimer et al., 1997) and KIBRA binding (Genevet et al.,
2010). Future studies will be needed to fully assess whether
a homologous Kibra-FRMD-Mer complex regulates Hippo
signaling in mammals.
To date, there is little evidence implicating mammalian homo-
logs of Ft or Crb in Hippo signaling. Of the four atypical mamma-
lian cadherins with extracellular homology to Ft, only Fat4 seems
to possess a cytoplasmic tail similar to that of Drosophila Ft.
Analysis of knockout mice revealed an essential role for Fat4 in
controlling PCP in inner hair cell orientation and neural tubeDevelopmental Cell 19, October 19, 2010 ª2010 Elsevier Inc. 497
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characterized by a loss of orientated cell division (Saburi et al.,
2008). None of these PCP-related phenotypes were reported in
mice lacking essential components of the Hippo kinase cascade,
such as Mst1/2 or Sav1 (Zhou et al., 2009; Lu et al., 2010; Song
et al., 2010; Lee et al., 2010; Lee et al., 2008). Conversely, the
phenotypes characteristic of mouse knockouts of Sav1 or
Mst1/2, such as hepatomegaly, were not reported in Fat4mutant
mice. It remains unclear whether Fat4 may participate in Hippo
signaling in yet-to-be-defined cellular contexts. Likewise, the
importance of Crb family proteins in mammalian apicobasal
polarity (reviewed in Bazellieres et al., 2009) and pathophysi-
ology is illustrated by the fact that mutations in human Crb1
lead to early-onset retinal degenerative diseases, including reti-
nitis pigmentosa and Leber congenital amaurosis (den Hollander
et al., 1999). But these Crb-deficient phenotypes are not obvi-
ously related to Hippo signaling. Interestingly, Fat4 and Crb3
have been implicated as potential tumor suppressors in breast
cancers (Qi et al., 2009; Karp et al., 2008), suggesting a possible
crosstalk between these proteins in certain tissue contexts.
Complexity of Mst1/2 Regulation and Substrates
in Mammals
Mst1/2 proteins have long been the subject of intense study
because of their involvement in stress-induced apoptosis
(reviewed in Radu and Chernoff, 2009). In this context, Mst1/2
are activated by autophosphorylation and caspase-dependent
cleavage (Graves et al., 1998, 2001; Glantschnig et al., 2002;
Lee and Yonehara, 2002), which liberates the 35 KDa
N-terminal kinase domain from a C-terminal autoinhibitory
domain; active kinase then translocates the nucleus and
promotes apoptosis by phosphorylating relevant substrates
such as Histone H2B (Cheung et al., 2003). However, the cas-
pase cleavage site of Mst1/2 is not conserved in Hpo, and
mutant alleles of hpo that encode an analogous 35 KDa
product lead to loss- rather than gain-of-function mutations in
Drosophila (Wu et al., 2003; Harvey et al., 2003). Indeed, the
35 KDa Mst1/2 cleavage products lack the C-terminal SARAH
domain that is required for Mst/Hpo-WW45/Sav binding in
Drosophila (Wu et al., 2003; Udan et al., 2003; Callus et al.,
2006). It, therefore, appears that at least in some contexts,
Mst1/2 are regulated differently and connect to their down-
stream effectors via different mechanisms compared to their
Drosophila counterpart. Indeed, studies in mouse livers indicate
that Mst1/2 cleavage correlates with YAP phosphorylation and
inactivation via a Lats1/2-independent mechanism, and this
cleavage is frequently lost in human HCCs (Zhou et al., 2009).
Mst1/2 activity is also regulated by heterodimerization with
RASSF family proteins (reviewed in Richter et al., 2009; Avruch
et al., 2009). The human genome encodes six distinct RASSF
family members (RASSF1 to -6), each of which contains a Ras
association (RA) domain and a C-terminal SARAH domain.
Most RASSF family members have been implicated as tumor
suppressors, and their expression is frequently inactivated
through epigenetic silencing in human cancers (reviewed in
Richter et al., 2009). Their tumor suppressor activity can often
be attributed, at least in part, to SARAH domain-mediated heter-
odimerization with Mst1/2. This interaction may activate Mst1/2
by targeting Mst1/2 to their endogenous activators and
substrates (Praskova et al., 2004) or by liberating Mst1/2 from498 Developmental Cell 19, October 19, 2010 ª2010 Elsevier Inc.their inhibitors (such as the kinase Raf-1) (Matallanas et al.,
2007). An exception is RASSF6, which has been reported to
inhibit Mst2 (Ikeda et al., 2009). The molecular relationship
between the Mst/Hpo-RASSF complex and the Mst/Hpo-
WW45/Sav complex remains to be defined: whereas a trimeric
complex of Mst2, WW45, and RASSF1A (or RASSF6) has been
reported in mammalian cells (Guo et al., 2007; Ikeda et al.,
2009), dRASSF and Sav bind to Hpo in a mutually exclusive
manner in Drosophila (Polesello et al., 2006). Another emerging
theme concerns the regulation of RASSF proteins by small
GTPases. In mammalian cell cultures, endogenous Nore1/
RASSF5was reported to bind active Ras upon serum stimulation
(Vavvas et al., 1998), and further studies implicated the Nore1-
Mst1 complex as a Ras effector that mediates the proapoptotic
effect of activated Ras (Praskova et al., 2004). Another small
GTPase, Rap1, has been implicated as a regulator of the
Nore1-Mst1 complex in lymphocyte trafficking and motility
(Katagiri et al., 2003).
Accompanying the complex mechanisms of Mst1/2 regulation
is the complexity of known Mst1/2 substrates. Besides the core
Hippo pathway components WW45, Mob1 and Lats1/2, Mst1/2
have been shown to phosphorylate a diverse array of substrates,
such as Histone H2B (Cheung et al., 2003), transcription factors
FOXO1 and FOXO3 (Lehtinen et al., 2006; Jang et al., 2007), and
the Lats1/2-related kinases Ndr1/Ndr2 (Vichalkovski et al.,
2008), mostly in response to apoptotic stimuli. It will be important
to define the contribution of these pathways to the overall tumor
suppressor function of Mst1/2, especially in the context of intact
mammalian tissues.
Future Directions for the Hippo Signaling Network
in Mammals
A notable feature of the mammalian Hippo pathway is the large
number of RASSF family proteins compared toDrosophila. While
the underlying reason for this difference is unknown at present,
one can speculate that the mammalian RASSF proteins may
have evolved to link Mst1/2 to a greater diversity of upstream
signals in mammals. Such complexity reinforces the emerging
view from genetic dissection of Hippo signaling in Drosophila
that the core Hippo kinase cascademay be viewed as a signaling
module that integrates diverse upstream inputs, possibly in
a context-dependent manner. In light of this, it is perhaps more
accurate to consider Hippo signaling as a complex network
rather than a discrete linear pathway. A major challenge in
the future is to identify the complete repertoire of cell surface
inputs into the Hippo signaling network in both Drosophila and
mammals.
As the nuclear effectors of the Hippo signaling pathway, YAP
and TAZ represent attractive points of crosstalk. Indeed, Sonic
hedgehog signaling is known to upregulate YAP transcription
in cerebellar granule neural precursors (Fernandez-L et al.,
2009). Conversely, YAP and TAZ can control BMP/TGF-b-
dependent Smad signaling (Alarco´n et al., 2009; Varelas et al.,
2008). In a recent study, Varelas et al. reported crosstalk
between the Hippo and the Wnt signaling pathways as well,
such that Lats1/2-phosphorylated and cytoplasmic-localized
TAZ protein inhibits Wnt signaling through direct physical inter-
action with the Dishevelled protein (Varelas et al., 2010). Since
Lats1/2-phosphorylated TAZ is inactive as a transcriptional
coactivator, this study revealed a hitherto unknown cytoplasmic
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pathway may restrict tissue growth not only by inactivating YAP/
TAZ’s oncogenic activity in the nucleus, but also by enhancing its
growth-suppressive activity in the cytoplasm. Future studies will
likely reveal additional modes of crosstalk between Hippo and
other signaling pathways, which may shed light on how different
developmental pathways are integrated to specify organs of
characteristic size and shape during animal development.
Physiological Function of Hippo Signaling
in Animal Development
Although the Hippo pathway was first discovered for its pivotal
role in restricting imaginal disc growth by promoting cell-cycle
exit and apoptosis, more recent studies in Drosophila have
expanded the function of this pathway into other developmental
contexts, such as the mitotic-to-endocycle switch of the poste-
rior follicle cells in adult egg chambers (Polesello and Tapon,
2007; Meignin et al., 2007; Yu et al., 2008), neuroepithelial cell
differentiation in larval optic lobe (Reddy et al., 2010), photore-
ceptor R8 subtype specification in pupal retina (Mikeladze-
Dvali et al., 2005), and dendrite morphogenesis of larval
sensory neurons (Emoto et al., 2006). These studies emphasize
two general physiological functions for Hippo signaling: coordi-
nating a timely transition from cell proliferation to cellular quies-
cence and ensuring proper cellular differentiation. These two
processes are intimately linked in many development contexts.
Studies of Hippo signaling in vertebrates have reinforced
these general themes. For example, overexpression of YAP in
murine intestine or chick neural tubes resulted in expansion of
progenitor cells and concomitant loss of differentiated cells
(Camargo et al., 2007; Cao et al., 2008). Likewise, loss of
WW45 led to progenitor cell hyperplasia and defective terminal
differentiation in skin, intestine, and lung epithelia (Lee et al.,
2008). In cell culture models of myogenesis and keratinocyte
differentiation, it was shown that Hippo signaling is activated at
the onset of cell differentiation and that YAP hyperactivation
led to failure of cell-cycle exit and terminal differentiation (Watt
et al., 2010; Lee et al., 2008). The loss of differentiated cell types
upon YAP hyperactivationmay explain, at least in part, why ubiq-
uitous inactivation of Hippo signaling resulted in increased organ
size in only selected tissues (Lee et al., 2008; Song et al., 2010).
In some developmental contexts, however, the often coupled
roles for Hippo signaling in promoting cellular quiescence and
differentiation may be separated from each other. For example,
Hippo signaling is required to maintain the terminally differenti-
ated hepatocytes of mammalian livers in a quiescent state.
Overexpression of YAP or loss of Mst1/2 leads to ectopic prolif-
eration of the differentiated hepatocytes (Dong et al., 2007;
Camargo et al., 2007; Zhou et al., 2009; Lu et al., 2010). In this
context, Hippo signaling regulates cell proliferation without an
obvious effect on hepatocyte differentiation. There are also
contexts in which the opposite is true. In blastocyst stagemouse
embryos, differential Hippo signaling activity leads to cyto-
plasmic and nuclear YAP localization in the presumptive inner
cell mass (ICM) (inside the blastocyst) and the presumptive tro-
phectoderm lining the exterior of the blastocyst, respectively
(Nishioka et al., 2009). This position-dependent Hippo signaling
activity may derive in part from the difference in the degree of
cell-cell contacts between the inside and the outside cells. Inthis context, cell-contact-mediated Hippo signaling regulates
cell-fate specification without inducing proliferation arrest. This
dedicated role in cell differentiation is reminiscent of the
requirement for Hippo signaling in photoreceptor R8 subtype
specification and dendrite morphogenesis in Drosophila,
although the latter involve postmitotic rather than proliferating
cells (Mikeladze-Dvali et al., 2005; Emoto et al., 2006). Thus,
Hippo signaling may regulate distinct cellular outcomes in
different contexts.
Hippo Signaling in Human Diseases and Cancers
Consistent with the critical roles of Hippo signaling inmammalian
physiology, mutations in Hippo pathway components have been
linked to human diseases. Besides Mer/NF2 as the tumor
suppressor underlying Neurofibromatosis 2, a heterozygous
missense mutation in TEAD1, Y421H, was identified in two inde-
pendent pedigrees as the cause of Sveinsson’s chorioretinal
atrophy (SCRA) (also known as helicoid peripapillary chorioreti-
nal degeneration), a rare autosomal dominant disease character-
ized by progressive lesions radiating from the optic disc involving
the retina and the choroid (Fossdal et al., 2004). In the recently
resolved three dimensional structure of the TEAD1-YAP or
the TEAD4-YAP complex, Y421 was shown to be engaged in
hydrogen bond and hydrophobic interaction with YAP (Chen
et al., 2010b; Li et al., 2010b). Accordingly, TEAD1/2/4 proteins
carrying the disease-mimicking mutation disrupted TEAD1/2/4-
YAP/TAZ binding (Kitagawa, 2007; Chen et al., 2010b; Li et al.,
2010b; Tian et al., 2010). It is unknown at present whether
SCRA lesions result from loss of heterozygosity or haploinsuffi-
ciency of the dominant Y421G allele. Identifying the relevant
target genes should shed light on the pathophysiological mech-
anism of SCRA.
Other than NF2/Mer, DNA mutations in tumor suppressor
components of the Hippo pathway are rare in human cancers
(http://www.sanger.ac.uk/genetics/CGP/cosmic/). Deletion of
WW45 was reported in two renal cancer cell lines (Tapon et al.,
2002), and mutations in Mob1 were found in two cDNAs derived
from a human melanoma and a mouse mammary carcinoma,
respectively (Lai et al., 2005). In contrast, there is increasing
evidence implicating epigenetic silencing as a prevalent mecha-
nism of inactivating Hippo pathway tumor suppressor genes.
Besides the frequent hypermethylation of RASSF family genes
in human cancers (Richter et al., 2009), hypermethylation of
Mst1/2 (in soft tissue sarcoma; Seidel et al., 2007) and Lats1/2
(in astrocytoma and breast cancers; Jiang et al., 2006; Takahashi
et al., 2005) has also been reported. More generally, decreased
expression of Mst1/2 (in colorectal and prostate cancers; Minoo
et al., 2007; Cinar et al., 2007) and Mob1 (in colorectal and lung
cancers; Kosaka et al., 2007; Sasaki et al., 2007) may be func-
tionally significant, irrespective of methylation status. miRNA-
mediated silencing of Hippo pathway tumor suppressors in
human cancers has also emerged, as exemplified by the
suppression of Lats2 expression by miR372 and miR373, two
related oncogenic miRNAs in testicular germ cell tumors
(Voorhoeve et al., 2006).
The YAP/TAZ-TEAD transcription factor complex represents
a common target of oncogenic transformation. Amplification of
the YAP gene locus has been reported at varying frequencies
in a wide spectrum of human and murine tumors, such asDevelopmental Cell 19, October 19, 2010 ª2010 Elsevier Inc. 499
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nomas of the lung, pancreas, esophagus, liver, and mammary
gland (Fernandez-L et al., 2009; Dai et al., 2003; Snijders et al.,
2005; Bashyam et al., 2005; Imoto et al., 2001; Zender et al.,
2006; Overholtzer et al., 2006). Interestingly, in nearly all cases,
the YAP amplicon also contains cIAP2, a mammalian homolog
of diap1, suggesting a potential cooperation between YAP and
cIAP2 in tumorigenesis. Consistently, comprehensive survey of
the most common solid cancer types revealed widespread and
frequent YAP overexpression in lung, ovarian, pancreatic, colo-
rectal, hepatocellular, and prostate carcinomas (Dong et al.,
2007; Steinhardt et al., 2008), and YAPwas shown to be an inde-
pendent prognostic marker for disease-free survival and overall
survival of HCC patients (Xu et al., 2009). A comprehensive
survey of TAZ protein expression across multiple tumor types
is unavailable at present. In one study focusing on mammary
tumors, TAZ overexpression was detected in 21% of primary
breast cancers (Chan et al., 2008). This study further suggested
that TAZ may govern the invasiveness of breast cancer cells.
Consistent with these findings, overexpression of YAP or TAZ
can induce anchorage-independent growth and EMT of
immortalized mammary and pancreatic epithelial cells in vitro
(Overholtzer et al., 2006; Zhao et al., 2008; Zhang et al., 2009a;
Chan et al., 2009; Dong et al., 2007). Interestingly, the YAP/
TAZ partner TEAD4 has also been reported to be amplified in
various cancers (Nowee et al., 2007; Skotheim et al., 2006;
Ade´laı¨de et al., 2007), and TEAD4 alone promoted anchorage-
independent growth of MCF10A cells in vitro (Chan et al.,
2009). Whether other TEAD homologs are amplified or overex-
pressed in human cancers remains to be determined. It is worth
noting that besides its role as a potent oncogene, YAP has also
been implicated as a potential tumor suppressor by potentiating
p73-mediated apoptosis (Strano et al., 2001; Basu et al., 2003;
Matallanas et al., 2007; Oka et al., 2008; Yuan et al., 2008). Para-
doxically, this proapoptotic activity of YAP was reported to be
activated (Matallanas et al., 2007) or inhibited (Oka et al., 2008)
by Lats1-mediated phosphorylation. Future studies are required
to determine whether the seemingly opposing function of YAP as
an oncoprotein versus a tumor suppressor is dictated by cell
contexts.
Concluding Remarks
Research in the past several years has greatly advanced our
understanding of the molecular mechanism and the physiolog-
ical function of the Hippo signaling pathway. These studies
have firmly established the Hippo signaling pathway as a central
mechanism that regulates organ size and tissue homeostasis in
species spanning from Drosophila to mammals. The funda-
mental importance of this pathway is further solidified by the
realization that dysregulation of Hippo signaling underlies
various human diseases including cancer.
Despite recent progress, our knowledge about this important
growth regulatory pathway remains incomplete. First and fore-
most, while a conserved Hippo kinase cascade has been estab-
lished, potentially important variations on this cascade await
characterization in mammals, and many of the upstream inputs
remain to be defined (Figure 1). A major challenge in the future
is to elucidate the molecular nature of these upstream signals,
the physiological contexts of their action, and the molecular500 Developmental Cell 19, October 19, 2010 ª2010 Elsevier Inc.mechanism by which they regulate the Kibra-Ex-Mer complex
and/or the core kinase cassette. Conversely, the outputs of the
pathway remain incompletely defined, especially in intact
mammalian tissues. Another challenge is to understand how
the growth-regulatory Hippo pathway is integrated with other
developmental pathways involved in pattern formation, cell
growth, survival, and differentiation to coordinately define the
characteristic size, shape, and cellular composition of a given
organ during animal development. Likewise, investigation of
how dysregulation of Hippo and other pathways cooperate to
drive tumorigenesis and other forms of human disease is likely
to be an active and exciting topic. Finally, small molecule modu-
lators of Hippo signaling may be exploited for tissue engineering
and regenerative medicine, as well as therapeutic intervention of
relevant human cancers.ACKNOWLEDGMENTS
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